☆ 4.7 Meeting Abstract

Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy

JOURNAL OF CLINICAL ONCOLOGY (2018)

主要评分表示论文的整体质量水平。次要评分独立反映论文的优点或缺点。

Discuss science. Find collaborators. Network.

Join a conversation

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now